Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte-and platelet-derived soluble mediators

Cytotherapy

Volumn 11, Issue 6, 2009, Pages 749-760

  Akkök, Çiǧdem Akalin ^a   Liseth, Knut ^a   Hervig, Tor ^a   Ryningen, Anita ^a   Bruserud, Øystein ^a   Ersvær, Elisabeth ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Autotransplantation; Cytokines; Leukocytes; Mobilized peripheral blood stem cells; Platelets

Indexed keywords

CD14 ANTIGEN; CD34 ANTIGEN; DIMETHYL SULFOXIDE; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; PERFORIN; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APHERESIS; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER PATIENT; CELL VIABILITY; CONTROLLED STUDY; CRYOPRESERVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKOCYTE; LYMPHOCYTE; MALE; MEDIATOR RELEASE; MONOCYTE; PRIORITY JOURNAL; SUPERNATANT; THAWING; THROMBOCYTE;

EID: 73649113788     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653240902980443     Document Type: Article

References (52)

1. Kessinger A, Schmit-Pokorny K, Smith D, Armitage J. Cryopreservation and infusion of autologous peripheral blood stem cells. Bone Marrow Transplant 1990;5:25-27
2. Alessandrino EP, Bernasconi P, Caldera D, Colombo A, Bonfchi M, Malcovati L, et al. Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: Analysis of 126 cases. Bone Marrow Transplant 1999;23:533-537
3. Donmez A, Tombuloglu M, Gungor A, Soyer N, Saydam G, Cagirgan A. Clinical side effects during peripheral blood progenitor cell infusion. Transfus Apher Sci 2007;36:95-101.
4. Nishihara G, Sakemi T, Ikeda Y, Baba N, Shimamoto Y. Multiple organ failure associated with dimethylsulfoxide and hydroxyethyl starch in autologous blood stem cell transplantation. Nephron 1996;72:356-357
5. Bauwens D, Hantson P, Laterre PF, Michaux L, Latinne D, Tourtchaninoff MD, et al. Recurrent seizure and sustained encephalopathy associated with dimethylsulfoxide-preserved stem cell infusion. Leuk Lymphoma 2005;46:1671-1674
6. Hentschke S, Hentschke M, Hummel K, Salwender HJ, Braumann D, Stang A. Bilateral thalamic infarction after reinfusion of DMSO-preserved autologous stem-cells. Leuk Lymphoma 2006;47:2418-2420
7. Chen-Plotkin AS, Vossel KA, Samuels MA, Chen MH. Encephalopathy, stroke, and myocardial infarction with DMSO use in stem cell transplantation. Neurology 2007;68:859-861
8. Calmels B, Lemarié C, Esterni B, Malugani C, Charbonnier A, Coso D, et al. Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product. Transfusion 2007;47:1268-1275
9. Cordoba R, Arrieta R, Kerguelen A, Hernandez-Navarro F. The occurrence of adverse events during the infusion of autologous peripheral blood stem cells is related to the number of granulocytes in the leukapheresis product. Bone Marrow Transplant 2007;40:1063-1067
10. Milone G, Mercurio S, Strano A, Leotta S, Pinto V, Battiato K, et al. Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cells in the infused suspension and patient age. Cytotherapy 2007;9: 348-355
11. Syme R, Bewick M, Stewart D, Porter K, Chadderton T, Glück S. The role of depletion of dimethyl sulfoxide before autografting: on hematologic recovery, side effects, and toxicity. Biol Blood Marrow Transplant 2004;10:135-141
12. Lemarie C, Calmels B, Malenfant C, Arneodo V, Blaise D, Viret F, et al. Clinical experience with the delivery of thawed and washed autologous blood cells, with an automated closed fuid management device: CytoMate. Transfusion 2005;45:737-742
13. Foïs E, Desmartin M, Benhamida S, Xavier F, Vanneaux V, Rea D, et al. Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells: Analysis of 952 autologous peripheral blood stem cell transplantations. Bone Marrow Transplant 2007;40:831-835
14. Akkök CA, Liseth K, Nesthus I, Løkeland T, Tefre K, Bruserud O, et al. Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation. Transfusion 2008;48:877-883
15. Akkök CA, Holthe MR, Tangen JM, østenstad B, Bruserud ø. Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells. Transfusion 2008; 49:354-361
16. Steward AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001;19(17):3771-3779
17. Boulassel MR, Herr AL, deB Edwardes MD, Galal A, Lachance S, Laneuville P, et al. Early lymphocyte recovery following autologous peripheral stem cell transplantation is associated with better survival in younger patients with lymphoproliferative disorders. Hematology 2006;11:165-170
18. Kim H, Sohn HJ, Kim S, Lee JS, Kim WK, Suh C. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006;37:1037-1042
19. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001;98:579-585
20. Hartwig D, Härtel C, Hennig H, Müller-Steinhardt M, Schlenke P, Klüter H. Evidence for de novo synthesis of cytokines and chemokines in platelet concentrates. Vox Sanguinis. 2002;82:182-190
21. Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions. Transfusion 1993;33(3):195-199
22. Foss B, Abrahamsen JF, Bruserud ø. Peripheral blood progenitor cell grafts contain high levels of platelet-secreted mediators. Transfusion 2001;41:1431-1437
23. Liseth K Abrahamsen JF, Bjørsvik S, Grøttebø K Bruserud ø. The viability of cryopreserved PBPC depends on the DMSO concentration and the concentration of nucleated cells in the graft. Cytotherapy 2005;7:328-333
24. Abrahamsen JF, Bakken AM, Bruserud ø. Cryopreserving human peripheral blood progenitor cells with 5-percent rather than 10-percent DMSO results in less apoptosis and necrosis in CD34+ cells. Transfusion 2002;42:1573-1580
25. Ryningen A, Wergeland L, Glenjen N, Gjertsen BT, Bruserud ø. In vitro crosstalk between fbroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proan-giogenic Interleukin 8. Leuk Res 2005;29:185-196
26. Ryningen A, Ersvaer E, øyan AM, Kalland KH, Vintermyr OK Gjertsen BT, et al. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low bcl-2:bax ratio and low levels of heat shock protein 70 and 90. Leuk Res 2006;30:1531-1540
27. Abrahamsen JF, Wentzel-Larsen T, Bruserud ø, Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment 16. kinetics better than the total CD34+ cell dose measured prefreeze in patients that receive more than 2 × 106 CD34+ cells/ kg. Cytotherapy 2004;4:356-362
28. Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform fow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 1998;34:61-70.
29. Liu CC, Walsh CM, Young JD. Perforin: structure and function. Immunology Today 1995;16:194-201.
30. Kim H, Yoon SC, Lee TY, Jeong D. Discriminative cytotoxicity assessment based on various cellular damages. Toxicol Lett 2009;184:13-17
31. Decker T, Lohmann-Matthes ML, Gifford GE. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 1987;138(3):957-962
32. Bruserud ø, Ryningen A, Olsnes AM, Stordrange L, øyan AM, Kalland KH, et al. Subclassifcation of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007;92(3):332-341
33. Boehlen F, Clemetson KJ. Platelet chemokines and their receptors: what is their relevance to platelet storage and transfusion practice? Transfus Med 2001;11:403-417
34. Ikeda K, Ohto H, Nemoto K, Yamamoto G, Kato K, Ogata T, et al. Collection of MNCs and progenitor cells by two separators for PBPC transplantation: A randomized crossover trail. Transfusion 2003;43:814-819
35. Ikeda K, Ohto H, Kanno T, Ogata T, Noji H, Ogawa K, et al. Automated programs for collection of mononuclear cells and progenitor cells by two separators for peripheral blood progenitor cell transplantation: comparison by a randomized crossover study. Transfusion 2007;47:1234-1240
36. Kumar A, Kharfan-Dabaja MA, Glasmacher A Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: A systematic review and meta-analysis. J Natl Cancer Inst 2009;101(2):100-106
37. Mehta J, Singhal S. Current status of autologous hematopoietic stem cell transplantation in myeloma. Bone Marrow Transplant 2008;42(1):S28-34.
38. Lane TA Bashey A Carrier E, Holman P, Castro J, Mullen M, et al. Improving the effciency of PBPC collection by preapheresis peripheral blood and mid-apheresis product measurements of CD34 cells. Cytotherapy 2004;318-327
39. Frère P, Pereira M, Fillet G, Beguin Y Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation. Eur J Haematol 2006;76(2):102-108
40. Calmels B, Houzé P, Hengesse J-C, Ducrot T, Malenfant C, Chabannon C. Preclinical evaluation of an automated closed fuid management device: Cytomate™, for washing out DMSO from hematopoietic stem cell grafts after thawing. Bone Marrow Transplant 2003;31:823-828
41. Rodríguez L, Velasco B, García J, Martín-Henao GA. Evaluation of an automated cell processing device to reduce the dimethyl sulfoxide from hematopoietic grafts after thawing. Transfusion 2005;45:1391-1397
42. Pfeffer PF, Hirschberg H. Cell-mediated lympholysis: A one-step microplate technique. In: Ferrone S, Solheim BG, editors. HLA typing: Methodology and clinical aspects. CRC Press, Inc, Boca Raton, Florida, USA 1982, issue 2, pages 83-97.
43. Lalier L, Cartron PF, Juin P, Nedelkina S, Manon S, Bechinger B, et al. Bax activation and mitochondrial insertion during apoptosis. Apoptosis 2007;12(5):887-896
44. Riley RD, Burchill SA, Abrams KR, Heney D, Sutton AJ, Jones DR, et al. A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. European J Cancer 2003;39(1):19-30.
45. Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD, et al. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 1998;392(6675):505-509
46. De Boer F, Dräger AM, Van der Wall E, Pinedo HM, Schuurhuis GJ. Changes in L-selectin expression on CD34-positive cells upon cryopreservation of peripheral blood stem cell transplants. Bone Marrow Transplant 1998;22:1103-1110
47. Hattori Y, Kato H, Nitta M, Takamoto S. Decrease of L-selectin expression on human CD34+ cells on freezethawing and rapid recovery with short-term incubation. Exp Hematol 2001;29(1):114-122
48. Windrum P, Morris TC, Drake MB, Niederwieser D, Ruutu T, EBMT Chronic Leukaemia Working Party Complications Subcommittee. Variation in dimethyl sulfoxide use in stem cell transplantation: A survey of EBMT centres. Bone Marrow Transplant 2005;36(7):601-603
49. Abrahamsen JF, Rusten L, Bakken AM, Bruserud ø. Better preservation of early hematopoietic progenitor cells when human peripheral blood progenitor cells are cryopreserved with 5 percent dimethylsulfoxide instead of 10 percent dimethylsulfoxide. Transfusion 2004;44:785-789
50. Galmes A, Gutiérrez A, Sampol A, Canaro M, Morey M, Iglesias J, et al. Lon-term hematological reconstitution and clinical evaluation of autologous peripheral blood stem cell transplantation after cryopreservation of cells with 5% and 10% dimethylsulfoxide at -80 degrees C in a mechanical freezer. Haematologica 2007;92(7):986-989
51. Rowley SD, Feng Z, Chen L, Holmberg L, Heimfeld S, MacLeod B, et al. A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch. Bone Marrow Transplant 2003; 31(11):1043-1051
52. Takaue Y, Abe T, Kawano Y, Suzue T, Saito S, Hirao A, et al. Comparative analysis of engraftment after cryopreservation of peripheral blood stem cell autografts by controlled- versus uncontrolled-rate methods. Bone Marrow Transplant 1994; 13(6):801-804